推荐产品
生物来源
goat
质量水平
抗体形式
purified antibody
抗体产品类型
primary antibodies
克隆
polyclonal
种属反应性
human
制造商/商品名称
Chemicon®
技术
ELISA: suitable
immunofluorescence: suitable
immunohistochemistry: suitable
western blot: suitable
运输
wet ice
特异性
腺病毒，六邻体组装。与Para 1-3、流行性感冒A & B或RSV无交叉反应。与HEp-2细胞无反应。
免疫原
来自5型腺病毒的六邻体。
应用
ELISA：>1:5,000
间接荧光显微镜检查。
免疫印迹：仅1 mM DTT和2%SDS中的未煮沸样品
免疫组化
最佳工作稀释度必须由最终用户进行确定
间接荧光显微镜检查。
免疫印迹：仅1 mM DTT和2%SDS中的未煮沸样品
免疫组化
最佳工作稀释度必须由最终用户进行确定
研究子类别
传染病 - 病毒
传染病 - 病毒
研究类别
传染病
传染病
该抗腺病毒抗体经验证可用于ELISA、IF、WB、IH检测腺病毒。
外形
IgG部分（纯度>95%）。 在PBS（0.01 M，pH 7.2）中，含0.1%叠氮化钠
形式：纯化
储存及稳定性
自收到之日起，在-20°下以未稀释的等分试样可保存12个月。应避免反复冻/融循环。
其他说明
浓度：请参考批次特异性浓缩物的检验报告。
法律信息
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
免责声明
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
未找到合适的产品？
试试我们的产品选型工具.
储存分类代码
12 - Non Combustible Liquids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Matthew Glen Robertson et al.
Molecular therapy oncolytics, 20, 659-668 (2021-04-06)
Encoding the sodium iodide symporter (NIS) by an adenovirus (Ad) is a promising strategy to facilitate non-invasive imaging and radiotherapy of pancreatic cancer. However, insufficient levels of NIS expression in tumor cells have limited its clinical translation. To optimize Ad-based
Lynette M Phillips et al.
Neuro-oncology, 23(11), 1911-1921 (2021-06-02)
Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that
Highly efficient and carcinoma-specific adenoviral replication restricted by the EGP-2 promoter.
W M Gommans, P M J McLaughlin, J A C Schalk, G M M Groothuis, H J Haisma, M G Rots
Journal of Controlled Release : Official Journal of the Controlled Release Society null
M Verónica Lopez et al.
PloS one, 4(4), e5119-e5119 (2009-04-02)
The clinical efficacy of conditionally replicative oncolytic adenoviruses (CRAd) is still limited by the inefficient infection of the tumor mass. Since tumor growth is essentially the result of a continuous cross-talk between malignant and tumor-associated stromal cells, targeting both cell
Frederick F Lang et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36(14), 1419-1427 (2018-02-13)
Purpose DNX-2401 (Delta-24-RGD; tasadenoturev) is a tumor-selective, replication-competent oncolytic adenovirus. Preclinical studies demonstrated antiglioma efficacy, but the effects and mechanisms of action have not been evaluated in patients. Methods A phase I, dose-escalation, biologic-end-point clinical trial of DNX-2401 was conducted
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门